Private Third-Party Audits Could Enhance FDA’s Manufacturing Risk Analysis
This article was originally published in The Tan Sheet
Executive Summary
Private and third-party audits could direct FDA to problematic facilities while easing some inspection burden on firms that already comply, but not replace FDA’s typical inspection duties.